Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Fig. 2

Mediation analyses for systolic blood pressure using weight loss as a factor at Week 40/42 (SURPASS 1–5 individual data). Data are least-squares mean ETD (95% CI). Data are taken from the safety population of each study. Percentage values represent the percent of blood pressure reduction mediated by weight loss. CI confidence interval, ETD estimated treatment difference, SBP systolic blood pressure, TZP tirzepatide, WL-D weight-loss dependent, WL-IND weight-loss independent

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840